Cosmo Pharmaceuticals N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CMOPF research report →
Price Chart
About the company
Cosmo Pharmaceuticals N. V. , a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally.
- CEO
- Giovanni di Napoli
- IPO
- 2017
- Employees
- 324
- HQ
- Dublin, DU, IE
Get TickerSpark's AI analysis on CMOPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.25B
- P/E
- -163.84
- Fwd P/E
- 607.78
- PEG
- 1.60
- P/S
- 10.42
- P/B
- 1.87
- EV/EBITDA
- -1639.06
- Div Yield
- 3.35%
- Gross Margin
- 45.52%
- Op Margin
- -13.37%
- Net Margin
- -6.18%
- ROE
- -1.21%
- ROIC
- -2.04%
Latest fiscal year · YoY change
- Revenue
- $104.82M-60.7%
- Gross Profit
- $48.77M-80.2%
- Op Income
- $-10,479,888
- Net Income
- $-3,630,478-102.7%
- EPS
- $-0.23-102.8%
- OCF Growth
- -107.2%
- FCF Growth
- -110.1%
- 52W High
- $169.90
- 52W Low
- $69.71
- 50D MA
- $79.71
- 200D MA
- $108.76
- Beta
- 1.49
- RSI (14)
- 40
- Avg Volume
- 269
No earnings-call transcripts are available for CMOPF yet.
- Free Float
- 50.2%
- Shares Outstanding
- 17.19M
- Float Shares
- 8.63M
Our CMOPF coverage
Recent articles, reports, and earnings notes.
No research on CMOPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CMOPF report →Cosmo N.V. (CMOPF) Q2 2026 Earnings Call Transcript
seekingalpha.com · Jul 23
Cosmo Pharmaceuticals N.V. (CMOPF) Q4 2025 Earnings Call Transcript
seekingalpha.com · Mar 9
Cosmo Pharmaceuticals (OTC:CMOPF) Stock Price Up 1.1% – Here’s What Happened
defenseworld.net · Dec 27
The Hair-Loss Cure That Just Sent This Stock Exploding 24%--Is Big Pharma Paying Attention?
gurufocus.com · Dec 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.